- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Key Metrics
- Market Cap (In Cr) 40758.5
- Beta 0.2
- Div. Yield (%) 0.76
- P/B 14.45
- TTM P/E 48.99
- Peg Ratio 3.74
- Sector P/E 24.66
- D/E -
- Open Price 18906.05
- Prev Close 19187.95
Analysis
-
1 Week7.11%
-
3 Months2.89%
-
6 Month9.04%
-
YTD-0.94%
-
1 Year-1.29%
- 25% Low risk
- 25% Moderate risk
- 25% Balanced Risk
- 25% High risk
- 25% Extreme risk
9 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
- Ratings
- Current
- Strong Sell
- 2
- Sell
- 0
- Hold
- 2
- Buy
- 1
- Strong Buy
- 4
Abbott India News
Rajesh Palviya of Axis Securities recommends 3 stocks to buy today — 30 Sept
3 min read . 30 Sep 2022
Stocks to Watch: Airtel, HCL, Delhivery, IGL, TechM, Tata Chemicals
3 min read . 10 Aug 2022
Debt free stock is 17% near to 52-week-high, ICICI Securities sees more upside
2 min read . 15 Jul 2022
This large cap pharma stock recommends final and special dividend: Key takeaways
1 min read . 08 Jun 2022Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 4919.27
- Selling/ General/ Admin Expenses Total
- 1086.89
- Depreciation/ Amortization
- 66.1
- Other Operating Expenses Total
- 57.26
- Total Operating Expense
- 3892.34
- Operating Income
- 1026.93
- Net Income Before Taxes
- 1079.73
- Net Income
- 798.7
- Diluted Normalized EPS
- 375.87
- Period
- 2021
- Total Revenue
- 4310.02
- Selling/ General/ Admin Expenses Total
- 918.82
- Depreciation/ Amortization
- 58.13
- Other Operating Expenses Total
- 53.77
- Total Operating Expense
- 3441.5
- Operating Income
- 868.52
- Net Income Before Taxes
- 925.95
- Net Income
- 690.69
- Diluted Normalized EPS
- 325.12
- Period
- 2020
- Total Revenue
- 4093.14
- Selling/ General/ Admin Expenses Total
- 929.42
- Depreciation/ Amortization
- 59.61
- Other Operating Expenses Total
- 59.3
- Total Operating Expense
- 3386.48
- Operating Income
- 706.66
- Net Income Before Taxes
- 802.69
- Net Income
- 592.93
- Diluted Normalized EPS
- 279.22
- Period
- 2019
- Total Revenue
- 3678.6
- Selling/ General/ Admin Expenses Total
- 914.55
- Depreciation/ Amortization
- 16.92
- Other Operating Expenses Total
- 47
- Total Operating Expense
- 3085.21
- Operating Income
- 593.4
- Net Income Before Taxes
- 698.85
- Net Income
- 450.33
- Diluted Normalized EPS
- 209
- Period
- 2018
- Total Revenue
- 3307.12
- Selling/ General/ Admin Expenses Total
- 802.68
- Depreciation/ Amortization
- 16.19
- Other Operating Expenses Total
- 46.66
- Total Operating Expense
- 2793.21
- Operating Income
- 513.91
- Net Income Before Taxes
- 621.48
- Net Income
- 401.22
- Diluted Normalized EPS
- 175.14
- Period
- 2017
- Total Revenue
- 2938.69
- Selling/ General/ Admin Expenses Total
- 717.7
- Depreciation/ Amortization
- 16.43
- Other Operating Expenses Total
- 56.1
- Total Operating Expense
- 2552.78
- Operating Income
- 385.91
- Net Income Before Taxes
- 436.49
- Net Income
- 276.65
- Diluted Normalized EPS
- 130.25
Forecast
Technical
- 5 Day18427.61
- 10 Day18131.72
- 20 Day18097.31
- 50 Day18881.54
- 100 Day18503.84
- 300 Day17893.1
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Dr Reddys Laboratories
- 4333.95
- -25.25
- -0.58
- 5078.8
- 3655
- 72389.74
- Torrent Pharmaceuticals
- 1551.4
- 4.35
- 0.28
- 1643.42
- 1235.88
- 52316.9
- Abbott India
- 19030.6
- -157.35
- -0.82
- 23751.02
- 15426.74
- 40758.5
- Alkem Laboratories
- 3283.85
- 30.4
- 0.93
- 4050
- 2835
- 38976.4
- Zydus Lifesciences
- 386.7
- 3.15
- 0.82
- 572.9
- 319.4
- 38752.23
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 10-Aug-22
- Quarterly Results
- 17-May-22
- Audited Results & Dividend
- 09-Feb-22
- Quarterly Results
- 12-Nov-21
- Quarterly Results
- 06-Aug-21
- Quarterly Results
- 18-May-21
- Audited Results & Final Dividend
- 09-Feb-21
- Quarterly Results
Company Profile
ABOUT Abbott India
- Industry Biotechnology & Drugs
- ISIN INE358A01014
- BSE Code 500488
- NSE Code ABBOTINDIA
Abbott India Limited is an India-based company that is engaged in pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolics, multi-specialty, vaccines and consumer health, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremalax (constipation), Pankreoflat (indigestion) and Duvadilan (preterm labor), among others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure and Glucerna, among others.
MANAGEMENT
- Sridhar Kadangode Director - Finance
- Krupa Anandpara Compliance Officer, Associate Director - Secretarial & Company Secretary
- Vivek Kamath Managing Director, Additional Director
- Kunal Chowdhury Commercial Director - GI Business
- Prateek Gupta Director - Commercial Excellence
- Rajan Kalantre Director - Business Human Resources
- Jejoe Karankumar Director - Medical Affairs
- Shantaprasad Nagarmath Commercial Director – Gennext, Vaccines and Consumer Health
- T. Prasad Commercial Director - Specialty Care
- Sandeep Reddy Associate Director - Women’s Health
Company Summary
ABBOTT INDIA SUMMARY
Abbott India is trading 0.82% lower at Rs 19030.60 as compared to its last closing price. Abbott India has been trading in the price range of 19285.0 & 18812.0. Abbott India has given -0.94% in this year & 7.11% in the last 5 days.
Abbott India has TTM P/E ratio 48.99 as compared to the sector P/E of 24.66. There are 9 analysts who have initiated coverage on Abbott India. There are 4 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 205.64 Crores in its last quarter.
Listed peers of Abbott India include Dr Reddys Laboratories (-0.58%), Torrent Pharmaceuticals (0.28%), Abbott India (-0.82%) etc.
FAQs about Abbott India
- 2 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 2 analysts have given a hold rating
- 1 analysts have given a buy rating
- 4 analysts have given a strong buy rating
- TTM P/E: 48.99
- Sector P/E: 24.66
- Dividend Yield: 0.76%
- D/E ratio: -
